Skip to content
Inciteful Med

Standard of Care Treatment Options: HSCT vs ERT

Last updated:

The two standard treatments for Mucopolysaccharidosis type 1 (MPS I) are Hematopoietic Stem Cell Transplantation (HSCT) and Enzyme Replacement Therapy (ERT). HSCT is the gold standard for severe Hurler syndrome to protect brain health, while ERT is used for milder forms or as a bridge to transplant.

Key Takeaways

  • • Hematopoietic Stem Cell Transplantation (HSCT) is the gold standard treatment for severe Hurler syndrome because donor cells can cross into the brain to halt cognitive decline.
  • • Enzyme Replacement Therapy (ERT) is the primary treatment for attenuated forms of MPS I and involves replacing the missing enzyme through weekly IV infusions.
  • • ERT is frequently used immediately upon diagnosis as a 'bridge to transplant' to strengthen an infant's body before undergoing HSCT.
  • • For optimal brain protection, HSCT should be performed as early as possible, ideally before your child reaches 12 months of age.
  • • Because neither treatment fully cures bone deformities or heart valve damage, lifelong care from a multidisciplinary team of medical specialists is essential.

Choosing the right treatment for Mucopolysaccharidosis type 1 (MPS I) is one of the most critical decisions you will make. While there is currently no cure, there are two primary “standard of care” treatments that can significantly change the course of the disease by providing the enzyme your child’s body is missing [1][2].

Two Ways to Replace the Enzyme

Both Hematopoietic Stem Cell Transplantation (HSCT) and Enzyme Replacement Therapy (ERT) work by introducing the alpha-L-iduronidase (IDUA) enzyme into your child’s system [1][2]. This enzyme then begins to clear the accumulated glycosaminoglycans (GAGs) from the cells [3].

1. Hematopoietic Stem Cell Transplantation (HSCT)

HSCT, often called a bone marrow or cord blood transplant, is the gold standard for children with severe Hurler syndrome [1][4].

  • How it Works: Healthy donor cells are transplanted into your child’s body [1]. Once these cells take hold (engraftment), they begin to produce the missing enzyme continuously [5].
  • The CNS Advantage: Unlike other treatments, some of the donor cells can cross into the brain and central nervous system (CNS) [4][1]. This is the only way to halt the progressive neurocognitive decline seen in the severe form of MPS I [4][6].
  • The Critical Window: For the best outcomes, HSCT should be performed as early as possible—ideally before 12 months of age, and generally before 30 months [4][7][8]. Because early intervention is crucial for protecting brain health, your medical team will move urgently to schedule the transplant within the safest, most effective window [9][10].

2. Enzyme Replacement Therapy (ERT)

ERT (brand name Aldurazyme or laronidase) is the primary treatment for the attenuated forms of MPS I (Hurler-Scheie and Scheie syndromes) [1][11].

  • How it Works: The missing enzyme is given through a weekly intravenous (IV) infusion [1][11].
  • Systemic Benefits: ERT is highly effective at reducing the size of an enlarged liver or spleen, improving growth, and helping with joint mobility and breathing [1][11].
  • The CNS Limitation: The most significant drawback of ERT is that it cannot cross the blood-brain barrier [12][13]. Because of this, it cannot treat or prevent the cognitive decline found in severe Hurler syndrome [1].

ERT as a Bridge to Transplant

While it may seem that HSCT and ERT are strictly separate paths, they are often used together in severe cases. Infants diagnosed with severe Hurler syndrome are typically started on ERT infusions immediately upon diagnosis [14][15]. This serves as a “bridge to transplant,” helping to clear GAGs, shrink an enlarged liver or spleen, and improve the child’s respiratory function [14][16]. By strengthening their bodies, ERT helps ensure they are in the best possible physical condition to safely undergo the stem cell transplant [16][17].

The Treatment Decision Matrix

Feature Severe (Hurler) Attenuated (Scheie)
Primary Treatment HSCT (Stem Cell Transplant) ERT (Weekly Infusions)
Immediate Step Often ERT as a “bridge” to HSCT ERT upon diagnosis
Goal Prevent brain decline & systemic damage Manage systemic symptoms & quality of life
Brain Protection Yes, HSCT halts cognitive decline No, ERT does not reach the brain

Shared Limitations: What Treatment Doesn’t “Cure”

It is important to have realistic expectations. Even with successful treatment, some areas of the body are very difficult for the enzyme to reach:

  • Bone Disease: Both treatments have limited success in reversing dysostosis multiplex (bone deformities) and hip dysplasia [18][19].
  • Heart Valves: Established damage to heart valves (like aortic or mitral stenosis) often persists or even progresses, sometimes requiring surgery later in life [20][21][14].
  • Eyes: While ERT cannot effectively clear GAGs from the cornea, successful HSCT can stabilize or improve corneal clouding over time [22][14].

Because of these limitations, children with MPS I require lifelong monitoring by a team of specialists, regardless of which treatment they receive [1][4].

Frequently Asked Questions

Should my child get HSCT or ERT for MPS I?
The recommended treatment depends on the severity of the disease. Severe Hurler syndrome is typically treated with a stem cell transplant (HSCT), while attenuated forms like Hurler-Scheie and Scheie syndromes are primarily treated with weekly enzyme replacement therapy (ERT).
Why is ERT given before a stem cell transplant for severe Hurler syndrome?
Enzyme replacement therapy is often used immediately after diagnosis as a bridge to transplant. It helps shrink enlarged organs and improves respiratory function, making the child's body stronger and safely preparing them for the stem cell transplant procedure.
Can enzyme replacement therapy (ERT) protect my child's brain?
Standard ERT cannot cross the blood-brain barrier to reach the central nervous system. Because of this limitation, it cannot prevent the cognitive decline seen in severe MPS I, making a stem cell transplant the preferred method for protecting brain health.
Is there a cure for Mucopolysaccharidosis type 1?
While there is currently no cure, standard treatments like HSCT and ERT replace the missing enzyme and significantly change the course of the disease. However, because they cannot fully repair bone deformities or heart valves, lifelong specialist monitoring is required.
When is the best time for a child with MPS I to receive a stem cell transplant?
For the best outcomes, a stem cell transplant should be performed as early as possible. Medical teams aim to schedule the procedure ideally before 12 months of age, and generally before 30 months, to maximize protection for the child's developing brain.

Questions for Your Doctor

  • • Based on my child's diagnosis, is hematopoietic stem cell transplantation (HSCT) or enzyme replacement therapy (ERT) the recommended primary treatment?
  • • If my child is severe, will we start ERT immediately to bridge them to transplant safely?
  • • If we choose HSCT, how quickly do we need to move to find a donor, and what is the optimal age window for my child's specific situation?
  • • How does the 'blood-brain barrier' affect the choice between these two treatments?
  • • What monitoring will be needed after treatment to check if the enzyme levels are sufficient (e.g., donor chimerism or urinary GAGs)?
  • • Since neither treatment fully cures bone or heart valve issues, what specialists (like orthopedic or cardiology) should be part of my child's long-term care team?

Questions for You

  • • What are my primary goals for my child's treatment (e.g., preserving cognitive function, improving mobility, or reducing organ size)?
  • • Have I discussed the risks and benefits of a stem cell transplant with a specialist?
  • • How will we manage the logistics of frequent enzyme replacement therapy infusions if that is the chosen path?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement.

    Hampe CS, Wesley J, Lund TC, et al.

    Biomolecules 2021; (11(2)) doi:10.3390/biom11020189.

    PMID: 33572941
  2. 2

    Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry.

    Clarke LA, Giugliani R, Guffon N, et al.

    Clinical genetics 2019; (96(4)):281-289 doi:10.1111/cge.13583.

    PMID: 31194252
  3. 3

    Mucopolysaccharidosis type I due to maternal uniparental disomy of chromosome 4 with partial isodisomy of 4p16.3p15.2.

    Katja K, Inga V, Ramona L, et al.

    Molecular genetics and metabolism reports 2020; (25()):100660 doi:10.1016/j.ymgmr.2020.100660.

    PMID: 33117653
  4. 4

    Early enzyme replacement therapy enables a successful hematopoietic stem cell transplantation in mucopolysaccharidosis type IH: Divergent clinical outcomes in two Japanese siblings.

    Yamazaki N, Kosuga M, Kida K, et al.

    Brain & development 2019; (41(6)):546-550 doi:10.1016/j.braindev.2019.01.008.

    PMID: 30755342
  5. 5

    Obstructive sleep apnea and craniofacial appearance in MPS type I-Hurler children after hematopoietic stem cell transplantation.

    Koehne T, Müller-Stöver S, Köhn A, et al.

    Sleep & breathing = Schlaf & Atmung 2019; (23(4)):1315-1321 doi:10.1007/s11325-019-01900-9.

    PMID: 31332621
  6. 6

    Cognitive outcomes and age of detection of severe mucopolysaccharidosis type 1.

    Grosse SD, Lam WKK, Wiggins LD, Kemper AR

    Genetics in medicine : official journal of the American College of Medical Genetics 2017; (19(9)):975-982 doi:10.1038/gim.2016.223.

    PMID: 28125077
  7. 7

    Incidence of Bloodstream Infections after Hematopoietic Stem Cell Transplantation for Hurler Syndrome.

    Dunseath C, O'Connor G, Mahulkar S, et al.

    Transplantation and cellular therapy 2023; (29(11)):707.e1-707.e4 doi:10.1016/j.jtct.2023.08.010.

    PMID: 37582469
  8. 8

    Mucopolysaccharidosis Type I.

    Kubaski F, de Oliveira Poswar F, Michelin-Tirelli K, et al.

    Diagnostics (Basel, Switzerland) 2020; (10(3)) doi:10.3390/diagnostics10030161.

    PMID: 32188113
  9. 9

    Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment.

    Shapiro EG, Nestrasil I, Rudser K, et al.

    Molecular genetics and metabolism 2015; (116(1-2)):61-8.

    PMID: 26095521
  10. 10

    Quantifying medical manifestations in Hurler syndrome with the infant physical symptom score: associations with long-term physical and adaptive outcomes.

    Ahmed A, Rudser K, King KE, et al.

    Molecular genetics and metabolism 2022; (136(1)):22-27 doi:10.1016/j.ymgme.2022.03.003.

    PMID: 35304037
  11. 11

    Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships.

    Al-Sannaa NA, Bay L, Barbouth DS, et al.

    Orphanet journal of rare diseases 2015; (10()):131 doi:10.1186/s13023-015-0344-4.

    PMID: 26446585
  12. 12

    Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease.

    Hsu YH, Liu RS, Lin WL, et al.

    Orphanet journal of rare diseases 2017; (12(1)):109 doi:10.1186/s13023-017-0649-6.

    PMID: 28595620
  13. 13

    Intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis type I, a randomized, open-label, controlled pilot study.

    Chen AH, Harmatz P, Nestrasil I, et al.

    Molecular genetics and metabolism 2020; (129(2)):80-90 doi:10.1016/j.ymgme.2019.11.007.

    PMID: 31839529
  14. 14

    Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model.

    Santi L, De Ponti G, Dina G, et al.

    Molecular genetics and metabolism 2020; (130(3)):197-208 doi:10.1016/j.ymgme.2020.05.001.

    PMID: 32439268
  15. 15

    Open issues in Mucopolysaccharidosis type I-Hurler.

    Parini R, Deodato F, Di Rocco M, et al.

    Orphanet journal of rare diseases 2017; (12(1)):112 doi:10.1186/s13023-017-0662-9.

    PMID: 28619065
  16. 16

    Mucopolysaccharidosis Type I in Mexico: Case-Based Review.

    Cantú-Reyna C, Vazquez-Cantu DL, Cruz-Camino H, et al.

    Children (Basel, Switzerland) 2023; (10(4)) doi:10.3390/children10040642.

    PMID: 37189891
  17. 17

    Long-term evolution of mucopolysaccharidosis type I in twins treated with enzyme replacement therapy plus hematopoietic stem cells transplantation.

    Carbajal-Rodríguez LM, Pérez-García M, Rodríguez-Herrera R, et al.

    Heliyon 2021; (7(8)):e07740 doi:10.1016/j.heliyon.2021.e07740.

    PMID: 34458603
  18. 18

    MPS I: Early diagnosis, bone disease and treatment, where are we now?

    Kingma SDK, Jonckheere AI

    Journal of inherited metabolic disease 2021; (44(6)):1289-1310 doi:10.1002/jimd.12431.

    PMID: 34480380
  19. 19

    Progression of Hip Dysplasia in Mucopolysaccharidosis Type I Hurler After Successful Hematopoietic Stem Cell Transplantation.

    Langereis EJ, den Os MM, Breen C, et al.

    The Journal of bone and joint surgery. American volume 2016; (98(5)):386-95 doi:10.2106/JBJS.O.00601.

    PMID: 26935461
  20. 20

    Residual glycosaminoglycan accumulation in mitral and aortic valves of a patient with attenuated MPS I (Scheie syndrome) after 6 years of enzyme replacement therapy: Implications for early diagnosis and therapy.

    Sato Y, Fujiwara M, Kobayashi H, et al.

    Molecular genetics and metabolism reports 2015; (5()):94-97 doi:10.1016/j.ymgmr.2015.10.014.

    PMID: 28649551
  21. 21

    Cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type I.

    Sugiura K, Kubo T, Ochi Y, et al.

    Molecular genetics and metabolism reports 2020; (25()):100662 doi:10.1016/j.ymgmr.2020.100662.

    PMID: 33101981
  22. 22

    Intrastromal Gene Therapy Prevents and Reverses Advanced Corneal Clouding in a Canine Model of Mucopolysaccharidosis I.

    Miyadera K, Conatser L, Llanga TA, et al.

    Molecular therapy : the journal of the American Society of Gene Therapy 2020; (28(6)):1455-1463 doi:10.1016/j.ymthe.2020.04.004.

    PMID: 32330426

This page provides educational information about MPS I treatments and is not intended as medical advice. Always consult your pediatric specialist and care team to determine the safest and most effective treatment plan for your child's specific diagnosis.

Stay up to date

Get notified when new research about Mucopolysaccharidosis type 1 is published.

No spam. Unsubscribe anytime.